Ivarmacitinib for advanced solid tumors after immunotherapy side effects
Treatments studied
Part of Cancer, Immune system & allergy clinical trials.
This trial tests a drug called Ivarmacitinib for people whose solid tumors stopped responding to immunotherapy due to side effects. It aims to see if Ivarmacitinib can help control the tumor while managing those side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have a solid tumor that spread or cannot be removed.
- You stopped immunotherapy because of side effects (immune-related adverse events).
- You have not already taken a JAK inhibitor (like Ivarmacitinib) for more than 30 days.
- Your organ function (liver, kidneys, blood counts) is good enough for this trial.
- You are willing to use reliable birth control if you could become pregnant or father a child.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a drug called Ivarmacitinib can prevent graft-versus-host disease (a common complication where donor cells attack your body) after a stem cell transplant from a half-matched donor. It is for people with certain blood cancers who are about to receive a transplant.
This study tests a new medication called ivarmacitinib for people with moderate-to-severe atopic dermatitis (severe itchy, inflamed skin) who haven't seen enough improvement from other similar treatments. Researchers want to see if switching to this new drug helps control symptoms better.
This trial tests a once-daily pill called Ivarmacitinib (a JAK inhibitor) taken alone to see if it can improve symptoms in people with rheumatoid arthritis who have not responded well to standard treatments like methotrexate. The study aims to find a more effective option for those who need better control of their RA.
This trial tests a new oral medication (Ivarmacitinib) for people aged 12–75 with moderate-to-severe atopic dermatitis (a chronic skin condition causing red, itchy skin). The goal is to see if it improves symptoms safely in both adolescents and adults.
This trial tests if adding a JAK1 inhibitor (ivarmacitinib) can help treat triple-negative breast cancer that stopped responding to immunotherapy. It's for people with advanced or metastatic TNBC who have already tried and failed anti-PD-1/PD-L1 treatment.
This trial tests a new daily pill, ivarmacitinib, for people with polymyalgia rheumatica (PMR). It may help control symptoms without needing steroids long-term.
Hear when a new Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.